Advertise with us
[August 05, 2010]
Reports HOT Stocks Alerts & Breaking New! -- RightSmile, Inc. (PINKSHEETS: RIGH), St. Bernard Software, Inc. (OTCBB: SBSW), Crown Equity Holdings Inc. (OTCBB: CRWE), Biotechnology company MabCure, Inc. (OTCBB: MBCI): Sign Up Today!
(M2 PressWIRE Via Acquire Media NewsEdge) www.OTCtipReporter.com Reports HOT Stocks Alerts & Breaking New! -- RightSmile, Inc. (PINKSHEETS: RIGH), St. Bernard Software, Inc. (OTCBB: SBSW), Crown Equity Holdings Inc. (OTCBB: CRWE), Biotechnology company MabCure, Inc. (OTCBB: MBCI) Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at HYPERLINK "http://www.OTCtipReporter.com/" www.OTCtipReporter.com _____________________________________________________________________________ RightSmile(R) Introduces LazerWhite 'Professional In-Home Lazer Teeth Whitening Solution'; RIGH Looks to the Holiday Season to Move Thousands of Units... At $49.95, Including a 'Free Gel for Life' Program PORT ST. LUCIE, FL -- 08/04/10 -- RightSmile, Inc. (PINKSHEETS: RIGH) (www.RightSmile.com), the leader in Cosmetic Laser Teeth Whitening, is pleased to announce the introduction of LazerWhite (www.LazerWhite.com).
LazerWhite delivers to the consumer, the ability to get Professional Laser Whitening results from the comfort of their home at an affordable price. LazerWhite will round out the brand offerings of RightSmile by providing the platform to address the internet, retail, TV shopping, international distribution and other markets, with branded LazerWhite and private-label iterations.
RIGH has partnered with Full Spectrum Media ("FSM") to assist in bringing LazerWhite to market. FSM is the firm responsible for the recent successful national campaign of SEXLETS gum, which now can be found in select Walgreens, 7-Elevens and boutique locations nationally. FSM will handle all internet sales and marketing of LazerWhite, and in conjunction with the RightSmile team, they will use their box-store connections to assure that LazerWhite is on their shelves for the holiday season.
LazerWhite is currently being introduced to major retailers across the US with a MSRP of $49.95; and in a move to add major value and completely separate themselves from the competition, LazerWhite will be offered to the consumer with a 'Free LazerGel For Life' program. Inside each LazerWhite kit is a special code that allows the consumer to register on-line, and receive free whitening gels for life, with the payment of shipping and handling. The Company looks to this added feature to make LazerWhite the 'Must Have' gift for the Christmas Season.
As part of a Shareholder appreciation campaign, and to allow direct sampling of the LazerWhite product, all Shareholders are invited to email Shareholders@RightSmile.com to request a $10.00 discount code to be used via the web at www.LazerWhite.com.
Furthermore, the Company would also like to announce it has completed the approximately 500,000,000 share reduction as previously reported. In addition and subsequent to this reduction, the Company further retired additional CDs.
About RightSmile : Based in Port St. Lucie, Florida, RightSmile, Inc. engages in the distribution of branded and private label Cosmetic Laser Teeth Whitening products addressing multiple markets.
The Company believes all remarks made in the release to be accurate to the best of its knowledge.
The foregoing press announcement contains forward-looking statements that can be identified by terminology such as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations could be affected by, among other things, uncertainties relating to our success in completing acquisitions, financing our operations, entering into strategic partnerships, engaging management and other matters disclosed by us in our public filings from time to time. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
_____________________________________________________________________________ St. Bernard Software Announces Acquisition of Red Condor Company Enhances Hybrid Security Offering and Expands Cloud-Based Service Platform SAN DIEGO, CA -- 08/04/10 -- St. Bernard Software, Inc. (OTCBB: SBSW), a leader in Web security appliances, today announced the acquisition of substantially all assets of Red Condor Inc., the award-winning provider of fully managed email security solutions.
The acquisition builds upon the success of St. Bernard's existing hybrid platform, which has served the SME market through a combination of high-performance appliances, software, and hosted security solutions. With the Web security market expected to grow to $2.3 billion by 2012, and the protection of leading applications such as email and messaging remaining a primary concern across global enterprises of all sizes, the acquisition of Red Condor's managed security solutions is a natural extension of St. Bernard's product portfolio and business strategy.
"This acquisition milestone is a truly exciting time for both St. Bernard and Red Condor as it creates great opportunities for growth with our shared hybrid security vision," said Lou Ryan, President and CEO at St. Bernard. "The strategic match we have found in Red Condor establishes greater breadth and depth in our hosted, hybrid and on-premises options and increases the overall value to our customers and partners. With the integration of Red Condor's carrier-grade technology and platform, we are perfectly positioned to accelerate our growth engine and work with an increasing and diversified base of customers across multiple security solutions." As a result of the acquisition, St. Bernard will gain over 1,900 new customers as well as Red Condor's extensive ISP and MSP partner network. St. Bernard's enhanced hybrid platform allows the company to extend new and unique value to subscribers of these previously underserved markets with a full suite of easy-to-use, cost-effective and scalable security solutions.
"Red Condor is widely recognized for the simplicity and scalability of its unique hybrid offerings," continued Ryan. "The Red Condor platform and the vision behind it, dovetail perfectly with St. Bernard's primary technology offering and reinforces our key attributes of value, simplicity, and performance." Founded in 2004, Red Condor has approximately 35 employees and is headquartered in Rohnert Park , California. The company's hosted and hybrid email spam filtering solutions have garnered numerous industry awards and recognition, and most recently proved to outperform competitive spam filters in an independent test of email filter accuracy by Miercom. The report not only validated Red Condor's hybrid technology offering, but also confirmed that the company had the highest block rate, zero false-positives and only one misclassified message for every 1,970 messages received during the one-week test. The complete results can be found at
For a complete description of the terms and conditions of this acquisition, please refer to the Form 8-K issued by the Company and filed with the SEC on August 3, 2010.
For further information on St. Bernard Software and its complete suite of security products, please visit www.stbernard.com. Additional information on Red Condor can be found at www.redcondor.com.
About St. Bernard Software St. Bernard Software develops and markets Internet security appliances and services that empower IT professionals to effectively, efficiently and intelligently manage their enterprise's Internet-based resources. Originally founded in 1995 as a market-leader in data security with its flagship product, Open File Manager?, the company is now recognized for delivering today's #1 Web filtering and security appliance, iPrism . With millions of end users worldwide in more than 5,000 enterprises, educational institutions, SMB, and government agencies, St. Bernard strives to deliver simple, high performance solutions that offer excellent value to our customers.
Based in San Diego, California, St. Bernard (OTCBB: SBSW) markets its solutions through a network of value added resellers, distributors, system integrators, OEM partners and directly to end users. For more information about St. Bernard Software, visit www.stbernard.com.
About Red Condor Red Condor is revolutionizing spam fighting with its next generation technology. Red Condor's highly accurate email filter, hybrid architecture Vx Technology?, and fully managed appliances lead to a dramatic reduction in the cost of owning a premium spam filter. With solutions for small business, as well as ISPs with millions of email inboxes, Red Condor has a cost-effective, timesaving solution that is rapidly gaining market share. The system's design has built-in zero tolerance for lost email, and a near zero false positive rate while achieving long-term spam block rates greater than 99%. Red Condor Archive is a secure message archiving service with lifetime retention and unlimited storage. The company's next-generation technology is backed by a 24x7 customer care center staffed by email security experts at Red Condor's headquarters. For more information visit www.redcondor.com.
2010 St. Bernard Software Inc. All rights reserved. The St. Bernard Software logo, iPrism, iGuard, the Red Condor Logo, and Vx Technology are trademarks of St. Bernard Software Inc. All other trademarks and registered trademarks are hereby acknowledged.
This press release may contain forward-looking statements that involve risks and uncertainties, as well as assumptions that, if they prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, among other things, any statements of the plans, strategies, and objectives of management for future operations; any statements concerning proposed new products, services, or developments; any statements about the expected growth of the web security market in 2012, statements about expected opportunities for growth and acceleration for growth and the increase in overall value to customers and vendors expected as a result of the acquisition, statements of belief and any statement of assumptions underlying any of the foregoing. The risks, uncertainties and assumptions referred to above include, among other things, St. Bernard's ability to retain any of the 1900 customers acquired as part of the acquisition, the ability to effectively merge the operation of Red Condor with that of St. Bernard and the ability to retain the assets acquired, performance of contracts by customers and partners; employee management issues; the timely development, production and acceptance of products and services and their feature sets; the challenge of managing asset levels, including inventory; the flow of products into third-party distribution channels; and the difficulty of keeping expense growth at modest levels while increasing revenues. These and other risks and factors that could cause events or our results to differ from those expressed or implied by such forward-looking statements are described in our most recent annual report on Form 10-K, as well as other subsequent filings with the Securities and Exchange Commission. We assume no obligation and do not intend to update these forward-looking statements.
_____________________________________________________________________________ Crown Equity Holdings Inc. Forward Stock Split Finalized LAS VEGAS, -- 08/04/2010 -- Crown Equity Holdings Inc. (OTCBB:CRWE) announced today that its previously announced 1 for 10 forward stock split was effective as of yesterday.
Ken Bosket, CEO of Crown Equity Holdings, said, "The Company and shareholders are elated to see their shares multiplied by ten. 10,000 shares became100,000 shares and 100,000 shares became 1,000,000 shares, and we believe this is just the beginning." This is the second forward split of Crown Equity Holdings' common stock in three years. The previous forward split was also a 1 for 10 forward split.
Crown Equity Holdings is a news service containing news from around the world, and an advertising media, consisting of : CRWE recently opened offices in Pakistan and Germany. Its mission is to become a world-renowned provider of media for information and up-to-date news.
Ken Bosket added, "Watch us grow, we are debt free, and our revenues have been increasing every quarter." About Crown Equity Holdings, Inc.: Crown Equity Holdings, Inc. is a company utilizing today's technology to advertise, promote and market public companies globally. CRWE's proprietary network technology allows their publishing department to get their content to millions of readers daily across the world. CRWE publishes financial content to all the major countries and covers all the accredited stock exchanges.
Crown Equity Holdings is currently in the process of expanding its in-house IT infrastructure. Although their current web page load time is better than 75% of other internet websites, when completed, the modifications will raise this load time to better then 90% of other internet websites while increasing website visitor capacity by 400%.
Crown Equity Holdings has also moved to a dedicated in-house advertising server, allowing for faster response and a wider variety of ad space offerings to those interested in advertising on their numerous internet and affiliate internet properties.
Forward-Looking Statements: This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by Crown Equity Holdings, (CRWE.OB) are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance, or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes _____________________________________________________________________________ MabCure, Inc. Files Provisional Patent in the U.S. for Ovarian Cancer Antibodies Antibodies Successfully Identified Ovarian Cancer in Recent Study NEW YORK -- 08/03/2010 -- Biotechnology company MabCure, Inc. (OTCBB: MBCI) today announced the company has filed a provisional patent application for its ovarian cancer diagnostic antibodies with the U.S. Patent and Trademark Office. The filing was based on positive results of a recent study that showed MabCure's tumor-specific monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent) and distinguished it from benign tumors of the ovaries or healthy blood obtained from men and women. The patent application covers a panel of MAbs, each of which is capable of diagnosing ovarian cancer, and several that can correctly distinguish between ovarian cancer and benign tumors.
"Filing the patent on these important discoveries is a significant step towards securing our intellectual property position and moving forward with potential strategic relationships and commercialization of what would be a highly specific serum diagnostic test for ovarian cancer," said Amnon Gonenne, Ph.D., CEO of MabCure.
In a blinded study of 54 blood samples, MabCure's MAbs correctly diagnosed 16 of the 17 ovarian cancers with a diagnostic sensitivity of 94 percent and 100 percent specificity. The samples were comprised of 17 patients with ovarian cancer, 5 patients with benign tumors of the ovaries, 24 healthy young females and 8 males.
"Beyond the value of our test to diagnose ovarian cancer in a highly accurate manner and with no false positives, the potential value of our proprietary MAbs is also in helping to identify tumor-specific antigens or cancer-specific targets for the ultimate treatment of ovarian cancer," said Gonenne.
About Ovarian Cancer Each year, 230,000 women worldwide are diagnosed with ovarian cancer, or cancer that forms in the tissues of the ovary, accounting for three percent of cancers in women. More than 125,000 women die from ovarian cancer annually, making it the fifth leading cause of cancer death in women and the deadliest of all gynecological cancers.
About MabCure's Technology MabCure has re-engineered classic hybridoma technology. Classic hybridoma technology is based on the generation of immortal hybrid cells or hybridoma, which follows the fusion of antibody-producing B-cells with myeloma tumor cells. Each hybridoma continuously manufactures a single monoclonal antibody. MabCure's enhanced technology has improved upon this process by increasing MAb yield, improving production times exponentially, and enhancing specificity.
MabCure has successfully generated hybridoma libraries for four different cancers that produce, respectively, antibodies to melanoma, to an aggressive form of prostate cancer, to ovarian cancer, and to colon carcinomas. These antibodies have been shown to be specific and "universal" to each cancer, respectively, (i.e. they recognize every cancer from different individuals having that particular disease and do not react with any normal antigen tested so far). These MAbs are the first candidates for the development of novel diagnostic tools, imaging agents and drugs to treat the corresponding cancers.
About MabCure MabCure is a U.S. biotechnology company whose mission is to change the perception of cancer as being a largely incurable disease. MabCure owns proprietary technology for the creation of unique and highly specific monoclonal antibodies (MAbs), which the company plans to develop as diagnostic tools, imaging agents and therapeutic drugs to treat lethal cancers. The company's initial focus is on the development of novel diagnostic tests for the early detection of ovarian, prostate, and colorectal cancers, each with multi-billion dollar global market potential. MabCure is also currently exploring the potential of its anti-melanoma antibodies for the development of imaging and therapeutic agents. The company is headquartered in Hasselt, Belgium. For more information about MabCure and to sign up for e-mail updates, visit www.mabcure.com.
This news release contains "forward-looking statements." Statements in this news release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the change of business focus of the management of the Company and the inability of the Company to pursue its current objectives. These forward-looking statements are made as of the date of this news release and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements.
_____________________________________________________________________________ About OTCtipReporter.com www.OTCtipReporter.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.
www.OTCtipReporter.com email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity. To subscribe to this free service, visit the OTCtipReporter Stock Report home page at
and Sign up Free For "Daily Stock Alerts".
Join us at
for a complimentary subscription to the most exciting online financial newsletter on the market.
Disclaimer: Verify all claims and do your own due diligence. OTCtipReporter.com profiles are not a solicitation or recommendation to buy, sell or hold securities. OTCtipReporter.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. OTCtipReporter.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), OTCtipReporter.com is owned and operated by OTCtipReporter.com. Neither OTCtipReporter.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this press-release, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since OTCtipReporter.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in OTCtipReporter.com statements and opinions and such statements and opinions cannot be considered independent. OTCtipReporter.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. OTCtipReporter.com services are often paid for using free-trading shares. OTCtipReporter.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.
Visit us for a full Disclaimer at:
((Comments on this story may be sent to firstname.lastname@example.org)) (c) 2010 M2 COMMUNICATIONS
Back To NFVZone's Homepage